Adenosine modulates a variety of cellular functions by interacting with specific cell surface G protein-coupled receptors (A 1 , A 2A , A 2B , and A 3 ) and is a potential mediator of angiogenesis through the A 2B receptor. The lack of a potent, selective A 2B receptor inhibitor has hampered its characterization. Our goal was to design a hammerhead ribozyme that would specifically cleave the A 2B receptor mRNA and examine its effect on retinal angiogenesis. Ribozymes specific for the mouse and human A 2B receptor mRNAs were designed and cloned in expression plasmids. Human embryonic kidney (HEK) 293 cells were transfected with these plasmids and A 2B receptor mRNA levels were determined by quantitative real-time RT-PCR. Human retinal endothelial cells (HRECs) were also transfected and cell migration was examined. The effects of these ribozymes on the levels of preretinal neovascularization were determined using a neonatal mouse model of oxygen-induced retinopathy (OIR). We produced a ribozyme with a V max of 515Ϯ125 pmol/min and a K cat of 36.1Ϯ8.3 min Ϫ1 (PՅ1ϫ10 Ϫ5 ). Transfection of HEK293 cells with the plasmid expressing the ribozyme reduced A 2B receptor mRNA levels by 45Ϯ4.8% (Pϭ5.1ϫ10 Ϫ5 ). Transfection of HRECs reduced NECA-stimulated migration of cells by 47.3Ϯ1.2% (Pϭ7ϫ10 Ϫ4 ). Intraocular injection of the constructs into the mouse model reduced preretinal neovascularization by 53.5Ϯ8.2% (Pϭ4.5ϫ10 Ϫ5 ). Our results suggest that the A 2B receptor ribozyme will provide a tool for the selective inhibition of this receptor and provide further support for the role of A 2B receptor in retinal angiogenesis. (Circ Res. 2003;93:500-506.) 
A ngiogenesis, the formation of new blood vessels from either preexisting vasculature or circulating stem cells, occurs as part of both normal development and pathologies of the retina. Retinal ischemia stimulates abnormal angiogenesis in conditions such as proliferative diabetic retinopathy (PDR) and retinopathy of prematurity (ROP). Substantial evidence supports a role for adenosine in promoting each step associated with angiogenesis. 1, 2 Adenosine can act as a mitogen in endothelial cells derived from numerous vascular beds to increase cell number, [3] [4] [5] [6] DNA synthesis, 7 cell migration, and vascularization. 8 Endothelial cells are known to have a very active adenosine metabolism. 9 Adenosine is a critical mediator of blood flow changes in response to ischemia and is a significant component of the retina's compensatory hyperemic response to ischemia, hypoxia, and hypoglycemia. 10 In the retinal microvasculature, adenosine and adenosine analogues cause concentration-dependent vasodilation. 11, 12 These observations strongly support a role for endogenously released adenosine as a key mediator of retinal blood flow during conditions of reduced oxygen supply. 11 Adenosine interacts with at least four subtypes of G protein-coupled receptors (A 1 , A 2A , A 2B , and A 3 ), 13,14 which are encoded by distinct genes and are differentiated based on their affinities for adenosine agonists and antagonists. 15 The A 1 and A 2A (high affinity) receptors are activated by submicromolar concentrations of adenosine and the A 2B and the A 3 receptors (low affinity) are activated when adenosine levels rise to micromolar range. 16 The receptors are also differentiated based on their signal transduction pathways. 14 A 1 and A 3 receptors interact with the G i and G 0 family to inhibit adenylate cyclase, whereas A 2A and A 2B receptors interact with G s and G q to stimulate adenylate cyclase. 15 Linden et al 16a have shown that overexpression of A 2B receptor results in cAMP accumulation and phospholipase C activation. On the other hand, A 2B receptor antagonists (eg, enprofylline) inhibit agonist stimulated cAMP accumulation. 17 In most cell types and organ systems, adenosine increases oxygen supply by activating the A 2 receptors and decreases oxygen demand by activating the A 1 receptor, demonstrating that adenosine may be a protective metabolite that rectifies imbalances between oxygen supply and demand. 18 A 2 receptors are associated with vessels and the A 2A and A 2B receptors have been implicated in angiogenesis. We have demonstrated that 5Ј-(N-ethylcarboxamido)adenosine (NECA) interacts with the A 2B receptor in human retinal endothelial cells (HRECs) and stimulates cell migration and proliferation. 19 NECA is a stable analogue of adenosine and activates all four adenosine receptors although with different potencies. Our findings and those of Sexl et al 20 are in contrast with the work of Van Daele et al, 21 who reported that adenosine stimulates only DNA synthesis in bovine aortic endothelial cells. These results suggest that endothelial cell populations differ in response to adenosine or adenosine analogues, and these differences may be attributed to differences in both the species and vascular beds studied. Takagi et al 22 24 also demonstrated high levels of A 2A receptor immunoreactivity in immature intravitreal neovascular formations in the canine oxygeninduced retinopathy (OIR) model. Our in vitro studies, and others, using human cells, including HRECs, 6 implicate the A 2B receptor in release of VEGF, IL-8, and FGF-2. In addition, the results of our in vivo studies in a mouse model of OIR also demonstrate the role of the A 2B receptor in retinal neovascularization. 25 Hammerhead ribozymes are catalytic RNA molecules that cleave phosphodiester bonds within RNA nucleotides, 26 and it has been proposed that ribozymes may act as potential inhibitors of cell proliferation. 27 Several groups have used antisense RNA to control the expression of the A 2B receptor in animals and in tissue culture. 28 -30 These results indicate several sites in the A 2B receptor mRNA that are accessible to antisense oligoribonucleotides and, hence, to ribozyme cleavage. Because of their catalytic ability, a lower concentration of ribozyme molecules is required to achieve efficient inhibition of mRNA expression. Therefore, ribozymes should be more effective than antisense RNA in reducing the expression of the A 2B receptor. 31 Our goal was to target the A 2B receptor with a hammerhead ribozyme to further demonstrate its role in angiogenesis. We designed and tested hammerhead ribozymes that specifically cleave the A 2B adenosine receptor mRNA of mouse and human ( Figure 1 ). We performed in vitro testing of the reaction kinetics of these ribozymes and determined the effect of these ribozymes on the migration of HRECs, and on the mRNA levels in HRECs and in human embryonic kidney (HEK) 293 cells. We characterized their effects on the level of preretinal neovascularization in the mouse model of OIR. Our results demonstrate that A 2B receptor ribozymes are effective at reducing the levels of the A 2B receptor mRNA and in inhibiting human retinal endothelial cell migration in vitro, as well as in reducing preretinal neovascularization in neonatal mice.
Materials and Methods

Synthetic RNA Targets and Ribozymes
We designed the A 2B receptor ribozymes based on the mouse sequence of the A 2B receptor (PubMed accession No. NM_007413). The sequences of theses ribozymes and targets are shown in Figure  1 . RNA oligonucleotides for the active and inactive mouse A 2B receptor hammerhead ribozymes and mouse and human targets were purchased from Dharmacon (Boulder, Colo) and deprotected following the manufacturer's protocol. RNA oligonucleotides were 5Ј-end labeled with [␥-32 P]-dATP (ICN) using polynucleotide kinase (Promega).
Time Course Analysis of Ribozyme Cleavage and Multiple-Turnover Kinetic Analysis
Time course analysis of ribozyme cleavage and multiple-turnover kinetic analysis were performed using the RNA oligonucleotides as previously described. [32] [33] [34] 
Cloning of the Hammerhead Ribozymes Into the rAAV Expression Vector
Two complementary DNA oligonucleotides (Life Technologies) were annealed in order to produce a double-stranded DNA fragment coding for each hammerhead ribozyme. All DNA oligonucleotides were synthesized with 5Ј-phosphate groups. The DNA oligonucleotides were designed to generate a cut HindIII site at the 5Ј-end and a cut SpeI site at the 3Ј-end after annealing. The DNA oligonucleotides were incubated at 65°C for 2 minutes and annealed by slow cooling to room temperature for 30 minutes. The resulting doublestranded DNA fragment was ligated into the HindIII and SpeI sites of the rAAV vector pTRUF-21 (UF Vector Core, http:// www.gtc.ufl.edu/gtc-home.htm). A self-cleaving hairpin ribozyme has been cloned downstream of the inserted hammerhead ribozymes into the SpeI and NsiI sites. This vector has the CMV/␤-actin chimeric enhancer-promoter and results in the hairpin ribozyme cleaving eight bases downstream of the 3Ј-end of the hammerhead ribozymes. We term the vector with the hairpin ribozyme alone p21NewHp. We cloned genes for inactive ribozymes (Figure 1 ). and verified in time course experiments that these ribozymes were inactive (data not shown). The ligated plasmids were transformed into SURE electroporation competent cells (Stratagene) in order to maintain the integrity of the inverted terminal repeats. The ribozyme clones were verified by sequencing.
Transfection of HRECs
HRECs were transfected with plasmids expressing the A 2B receptor ribozyme constructs as previously described. 35, 36 
Relative Quantitative RT-PCR
Relative quantitative RT-PCR was performed on RNA isolated from HRECs transfected with plasmids expressing ribozymes (A 2B Rz2 active and inactive) and p21NewHp. RNA was isolated from transfected HRECs using either the GenElute Direct mRNA Miniprep Kit (Sigma) for mRNA or the TRIzol Reagent (Invitrogen) for total RNA. Reverse transcription was accomplished using Super- script reverse transcriptase and a random hexamer (Invitrogen) according to manufacturer's protocols.
PCR reactions to determine A 2B receptor mRNA levels used gene-specific DNA oligonucleotides synthesized by Invitrogen (5Ј-GTACGTGGCGCTGGAGCTGG-3Ј and 5Ј-CTTGCTCGGGT-CCCCGTGAC-3Ј). The linear range of the amplification of the A 2B receptor RT-PCR product was determined by using a master PCR mix ( ). This master mix was separated into eight 0.2 mL tubes, and amplification was performed with an annealing temperature of 61°C. Samples were removed at evennumbered cycles starting at cycle 26. For each PCR sample, 5 L was removed and 2 L of formamide dye mix was added. The reaction products were separated on a 6% polyacrylamide-8 mol/L urea gel. Dried gels were analyzed on a Molecular Dynamics PhosphoImager (Amersham) to determine the linear range of amplification. For this oligonucleotide pair, cycle number 34 was determined to be within the linear range of amplification and was used in subsequent experiments.
In the relative quantitative RT-PCR assays the level of A 2B receptor mRNA was determined within each sample relative to an internal ␤-actin standard. ␤-actin mRNA levels were determined using the QuantumRNA ␤-actin primer/competimer oligonucleotide set from Ambion. The competimer oligonucleotide pair from the ␤-actin primer set anneals to the same targets as the primer oligonucleotide pair but they are blocked at their 3Ј-ends to prevent extension. This primer/competimer oligonucleotide set allowed us to determine the ratio of primer to competimer that yields a ␤-actin PCR fragment that is approximately equal molar to the A 2B receptor PCR product. To determine the ratio of the primer/competimer oligonucleotide set required to achieve this, PCR reactions were performed as described above and amplification proceeded for 34 cycles. The ratio of primer to competimer oligonucleotide was determined to be 10:1 at a final concentration of 0.4 mol/L for the combined primer/competimer mixture.
Migration Assays on Transfected HRECs
Transfected cells were assayed for their ability to migrate in response to NECA using a modified Boyden chamber assay as previously described. 37 Cells (30 000 cells/well) were added to the bottom wells of modified Boyden chambers, which are then fully assembled with a collagen-coated, pyrrolidone-and pyrogen-free porous membrane. The cells adhere to the membrane for 4 hours at 37°C, after which 50 L of the solution containing NECA was added to the wells. The chambers were then returned to 37°C for 12 hours to allow cell migration. The chambers were then disassembled and the membranes scraped on the side where the cells have adhered. The membranes are then fixed and stained with hematoxylin and eosin. Individuals masked to the identity of treatment counted the migrated cells. Control cells, transfected with p21NewHp, were compared with cells transfected with the ribozyme constructs. 10% FBS in DMEM was used as a positive control and DMEM alone as the negative control. Each test condition was assayed with a minimum of six replicate wells. Migrating cells were counted using a light microscope, and the number of migrating cells per well were calculated by averaging the number of nuclei counted in three separate, high-power (ϫ400) fields. The values for the six replicate wells were then averaged. Each migration experiment was repeated a minimum of three times representing cultures derived from three donors.
Transfection of HEK293 Cells
HEK293 cells were grown to 90% confluence on 150-mm plates and transfected with the plasmid constructs using Lipofectamine 2000 reagent (Invitrogen) according to manufacturer's protocol. The cells were harvested at 72 hours after transfection.
Real-Time RT-PCR
Messenger RNA was isolated from transfected HEK293 cells or HRECs using the GenElute Direct mRNA Miniprep Kit from Sigma. The cDNA was synthesized using either 2 or 4 g of total RNA and TaqMan Reverse Transcription Reagents (PE Applied Biosystems) in 100 L RT reaction. TaqMan real-time PCR analysis was applied using 1 L cDNA per reaction and SYBR Green PCR Core Reagents on ABI Prism Sequence Detection System 5700 (PE Applied Biosystems). In each experiment, a standard curve for each primer pair was obtained using a serial dilution of total RNA samples prepared from cells that overexpressed A 2B adenosine receptor. At the end of the PCR cycle, a dissociation curve was generated to ensure the amplification of a single product and the threshold cycle time (Ct values) for each gene was determined. Relative mRNA levels were calculated based on the Ct values and normalized to one of the following housekeeping genes: ␤-actin, cyclophilin, and ribosomal protein S9 (100%).
Statistical Analysis
All statistical analysis was done using the Student t test in Microsoft Excel. Values of PϽ0.001 are indicated with an asterisk on the graphs.
Animals
All animal procedures used were in agreement with institutional guidelines and with the NIH Guide for the Care and Use of Laboratory Animals and approved by the University of Florida Institutional Animal Care and Use Committee. Six timed pregnant C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, Maine). A total of 36 mouse pups were used for these studies.
Intraocular Injection Into the Mouse Model of Oxygen-Induced Retinopathy
In the neonatal mouse model of OIR, 7-day old mice were placed with their nursing dams in a 75% oxygen atmosphere for 5 days. 38 On return to normal air, these mice develop retinal neovascularization, with peak development occurring 5 days after their return to normoxia. The pups received a 0.5-L intravitreal injection of plasmid (2 mg/mL) OD on postnatal day one (P 1 ). After the fifth day following return to normoxia (P 17 ), the animals were euthanized, and the eyes removed and fixed in 4% paraformaldehyde and embedded in paraffin. Three hundred serial sections (6 m) were cut sagittally through the cornea parallel to the optic disc. Every thirtieth section was placed on slides and stained with hematoxylin-eosin. This results in a total of 10 sections from each eye being scored in a masked fashion using light microscopy by counting endothelial cell nuclei extending beyond the inner limiting membrane into the vitreous. 38 The efficacy of treatment with each plasmid was then calculated as the percent average nuclei per section in the injected eye versus the uninjected contralateral eye.
Results
Time Course Analysis of Ribozymes
Time course experiments indicated that A 2B receptor ribozymes rapidly cleaved synthetic targets either under standard in vitro conditions (20 mmol/L MgCl 2 ) or at room temperature in physiological magnesium conditions ( Figure  2) . Figure 2A is an autoradiograph from a 10% polyacrylamide-8 mol/L urea gel used to separate the products of cleavage of the A 2B Rz2 on the mouse A 2B target for reactions performed at 37°C and in 20 mmol/L MgCl 2 . Figure 2B shows the graphical representation of the gel in Figure 2A and of the A 2B Rz1 and the mouse target. This analysis was performed to determine the initial velocities for multipleturnover reactions. This interval is typical when less than 15% of the substrate has been digested. The A 2B Rz2 ribozyme exhibited a high rate of cleavage at 37°C in 20 mmol/L MgCl 2 with 15% cleavage occurring at less than one minute. Because this interval was inconvenient for multiple-turnover kinetic analysis, we dropped the reaction temperature to 25°C in 1 mmol/L MgCl 2 ( Figure 2C ).
Active A 2B Rz2 Cleaves Both Mouse and Human Targets
The active A 2B Rz2 ribozyme was designed to specifically cleave the mouse target sequence, but also cleaves the human target ( Figure 3 ). As shown in Figure 3B the mouse target has a C at the 3Ј-end, and this will pair with a G in the ribozyme (Figure 1 ). The human target has a U at the 3Ј-end, and this will still form a non-Watson-Crick base pair with the G in the ribozyme and still permit cleavage.
Multiple-Turnover Kinetic Analysis of Ribozymes
Multiple-turnover kinetic analysis was performed on both A 2B receptor ribozymes, and the kinetic parameters were determined (Table) . Each analysis was performed a minimum of three times (PՅ1ϫ10 Ϫ5 ). Reactions were done at both 37°C in 20 mmol/L MgCl 2 (standard conditions) and at 25°C in 1 mmol/L MgCl 2 . The reactions at 37°C were terminated at 6 minutes for A 2B Rz1 and one minute for A 2B Rz2. The reactions at 25°C were terminated at 3 minutes for A 2B Rz2. Based on K cat , A 2B Rz2 was 20-fold more active than A 2B Rz1 under standard conditions, and retained good activity even in low magnesium and temperature. The A 2B Rz2 was as active under these conditions as the naturally occurring hammerhead (from TRSV satellite RNA) under standard conditions. 39 Because this A 2B Rz2 was more potent than A 2B Rz1, we used it exclusively for experiments in cell culture and in mice.
Effect of A 2B Receptor Ribozymes on A 2B Receptor mRNA Levels
The active A 2B receptor ribozyme reduced A 2B receptor mRNA levels in both HRECs and HEK293 cells to 70.5Ϯ5.4% (Pϭ0.003) and 55.1Ϯ4.8% (Pϭ5.1ϫ10 Ϫ5 ), respectively. Figure 4 shows the results of both relative quantitative RT-PCR and real-time RT-PCR analysis on mRNA isolated from HRECs and HEK293 cells transfected with the active and inactive versions of the A 2B receptor ribozyme and with the control plasmid. As expected, the inactive A 2B receptor ribozyme did not reduce mRNA levels. Figure 3 . A, Time course of cleavage analysis of the active mouse A 2B receptor ribozyme 2 on the mouse (diamonds) and human (squares) RNA oligonucleotide targets. Reactions were performed at 37°C in 20 mmol/L MgCl 2 with a ribozyme to target ratio of 1:10. B, The A 2B receptor ribozyme was specifically designed to cleave the A 2B receptor mRNA from mouse, but the A 2B receptor ribozyme 2 is also capable of cleaving the human A 2B receptor mRNA. These targets differ in a single base (boxed), but the ribozyme will still anneal to the complete human target. For the conditions, 37/20 means that the reactions were carried out at 37°C and 20 mmol/L MgCl 2 and 25/1 means that the reactions were carried out at 25°C and 1 mmol/L MgCl 2 . 
Kinetic Parameters Determined for the Two A 2B Hammerhead Ribozymes Using Multiple-Turnover Kinetic Analysis
Effect of A 2B Receptor Ribozymes on Migration of HRECs
Plasmids expressing ribozymes or the cloning vector p21NewHp were transfected into HRECs to determine their effect on cell migration in a modified Boyden chamber. Cells transfected with plasmid coding for active A 2B Rz2 reduced migration of cells to an average of 52.7Ϯ1.2% (Pϭ7ϫ10 Ϫ4 ) when compared with the p21NewHp control at increasing concentrations of NECA (10 and 100 ng/mL), and cells transfected with plasmid coding for the inactive A 2B Rz2 reduced migration of cells to an average of 86.8Ϯ9.0% (Pϭ0.07) ( Figure 5 ).
Effect of A 2B Receptor Ribozymes on Neovascularization in the Neonatal Mouse Model of OIR
Plasmids expressing the ribozymes or the cloning vector p21NewHp were injected intravitreally on postnatal day one in the right eye of mouse pups, with no injection in the left eye. The pups and their dams were taken through the OIR. 38 The extent of retinal angiogenesis was determined and the results are shown in Figure 6 . Whereas p21NewHp had no effect on retinal angiogenesis, the active A 2B Rz2 reduced the average number of nuclei per section on average by 53.5Ϯ8.2% (Pϭ4.5ϫ10 Ϫ5 ). The inactive A 2B Rz2 reduced the average number of nuclei per section on average by 10.5Ϯ7.4% (Pϭ0.3). Figure 7 shows representative sections through a left-uninjected eye and a right eye injected with the active A 2B Rz2 in the same mouse pup.
Discussion
We have developed a hammerhead ribozyme that specifically cleaves the mouse and human adenosine A 2B receptor mRNAs (Figures 2 and 3) . We have demonstrated that this ribozyme reduces the expression of the A 2B receptor mRNA and the function of the A 2B receptor in HEK293 cells and HRECs, respectively (Figures 4 and 5 ). We found a 30% reduction in the A 2B receptor mRNA signal in HRECs and a 45% reduction in the A 2B receptor mRNA signal in HEK293 cells transfected with the active ribozyme compared with cells transfected with the control plasmid. The difference in the ability of the active ribozyme to reduce receptor mRNA levels between the two cell types most likely results from differences in transfection efficiency. This reduction in expression of the A 2B receptor mRNA correlated with a reduction in A 2B receptor function that we found in transfected HRECs. The chemotactic migration of HRECs across a porous membrane toward solutions containing increasing concentrations of NECA is dependent on the presence of A 2B receptors on the cell surface. 3, 19 We found that the number of migrating cells diminished to 47% in cells expressing the active ribozyme relative to cells transfected with the empty vector. The reduction in migration of HRECs transfected with a plasmid expressing the active A 2B receptor ribozyme suggests that cell surface levels of the A 2B receptor protein have been reduced due to inhibition of expression of the A 2B receptor mRNA by the ribozyme. These results provide strong evidence that cleavage of the A 2B receptor mRNA reduces expression of the protein in cultured cells to a level that significantly inhibits the cellular function of the A 2B receptor.
We also demonstrate that the active ribozyme inhibits preretinal neovascularization in vivo in a mouse model of OIR ( Figure 6 ). Preretinal neovascularization was reduced 53% in eyes injected with the plasmid expressing the active ribozyme. These results suggest that this reduction in neovascularization is a result of ribozyme inhibition of the expression of the A 2B receptor and demonstrate that this ribozyme could be useful for in vivo studies of A 2B receptor function in retinopathies. By selectively reducing the expression of the A 2B receptor mRNA, we are able to inhibit preretinal neovascularization in the mouse model of OIR and provide further evidence for the involvement of the A 2B receptor in retinal angiogenesis.
One result of this study was to separate the inhibitory effects of the active ribozyme into its catalytic and antisense effects. Antisense DNA oligonucleotides have been shown to inhibit the physiological activity of the A 2B receptor in cultured cells. 29 We attribute the reduced migration after treatment with the catalytically inert inactive ribozyme to be caused by a minor antisense effect ( Figure 5 ) rather than RNA reduction. Injection of the inactive ribozyme into the mouse model demonstrates that only a small portion of this reduction can be attributed to an antisense effect. Therefore, there is, at most, a minor antisense contribution in the reduction of preretinal neovascularization in the animal model. We conclude that ribozyme genes delivered as naked DNA lead to a substantial reduction in neovascularization in this model due to the catalytic activity of the ribozyme.
Finally, this study demonstrates the utility of using ribozymes to study complex physiological pathways. We successfully transfected human cells and an in vivo mouse model with a plasmid expressing a hammerhead ribozyme that reduced the expression of a single target mRNA. We were able to quantify the effects of the ribozyme through functional assays of the target. We will be able to use routine plasmid transfection of cells with vectors expressing the active ribozyme to study how inhibition of A 2B receptor expression affects other components of this pathway. We also demonstrate that injection of the plasmid expressing the A 2B receptor ribozyme into the mouse model reduces preretinal neovascularization. This model will allow us to further dissect the role of the A 2B receptor in angiogenesis. 
